Home Dermatology PDF: Dupilumab for Moderate-to-Severe Atopic Dermatitis
PDF: Dupilumab for Moderate-to-Severe Atopic Dermatitis
$1.99
PDF Download: Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option.